Match tier Listed
Presence Current · Arkansas
Last published 2026
Sources OpenAlex · ORCID
Refreshed 2026-08-20
William E. Fantegrossi profile photo

William E. Fantegrossi

Federal Grant PI High Impact

Professor

Also affiliated: Oregon National Primate Research Center (2008); University of Maryland, Baltimore (2024); National Institutes of Health (1997); Apple (Israel) (2021); National Institute on Drug Abuse (2016); Emory Healthcare (2006–2007); Children's Hospital of Philadelphia (2020); Uniformed Services University of the Health Sciences (1996); Emory University (2005–2010); American University (1998); Georgia State University (2007); Virginia Commonwealth University (2014); University of Michigan (1999–2011); University of Arkansas Medical Center (2010–2025); Hunter College (2010); National Institute of Diabetes and Digestive and Kidney Diseases (1997); National Institute on Alcohol Abuse and Alcoholism (2016); Deutsch Amerikanisches Institut Saarland (2004); Arkansas Department of Agriculture (2015–2017); Emory National Primate Research Center (2007–2010); University of Pennsylvania (2020); Walter Reed Army Institute of Research (1995)

Faculty Researcher

Pharmacology & Toxicology, College of Medicine

41 h-index 166 pubs 5,193 cited

  • Animals
  • Male
  • Mice
  • Dose-Response Relationship, Drug
  • Humans
  • Hallucinogens
  • N-Methyl-3,4-methylenedioxyamphetamine
  • Indoles
  • Cannabinoids
  • Central Nervous System Stimulants
  • Motor Activity
  • Rats
  • Substance-Related Disorders
  • Behavior, Animal
  • Reinforcement, Psychology

Biography and Research Information

OverviewAI-generated summary

William E. Fantegrossi's research program focuses on the pharmacological effects and toxicity of various classes of psychoactive drugs, with a particular emphasis on substances of abuse and potential therapeutic agents. His work investigates the interactions of these compounds with specific receptor systems, including cannabinoid and serotonin receptors, and their impact on behavior and physiological responses in preclinical models. Fantegrossi has studied the abuse liability, neurocognitive effects, and withdrawal symptoms associated with novel synthetic cannabinoids, phencyclidine analogs, and substituted amphetamines.

His research also extends to the potential therapeutic applications of compounds like MDMA and its analogs for conditions such as autism spectrum disorder. Fantegrossi has received federal funding for training in systems pharmacology and toxicology. His scholarly contributions are evidenced by a high h-index of 41, over 165 publications, and more than 5,170 citations. He actively collaborates with researchers at the University of Arkansas for Medical Sciences, including Brenda M. Gannon, Hannah E. Shaw, Jeffery H. Moran, and Lauren R. Fitzgerald, and leads a research group.

Metrics

  • h-index: 41
  • Publications: 166
  • Citations: 5,193

Selected Publications

  • Interoceptive effects of N1-substituted lysergamides in rats: role of agonist affinity at 5-HT receptors and in vivo metabolism to lysergic acid diethylamide (LSD) (2026)
    Journal of Pharmacology and Experimental Therapeutics DOI OpenAlex
  • Behavioral and Pharmacokinetic Implications of Synthetic Cannabinoid Receptor Agonist and Benzodiazepine Co-Administration in C57BL/6 Mice (Abstract ID: 221452) (2026)
    Journal of Pharmacology and Experimental Therapeutics DOI OpenAlex
  • Effects of Psychedelics Lysergic Acid Diethylamide and <i>R</i> (–)-2,5-Dimethoxy-4-Iodoamphetamine on Oral Opioid Consumption and Naloxone-Precipitated Withdrawal in Male C57Bl/6J Mice (2026)
    Psychedelic Medicine DOI OpenAlex
  • Outpacing Emerging Drug Threats: Validation of ToxBox Kits That Automate LC-MS/MS Analyses (2026)
    Chemical Research in Toxicology DOI OpenAlex
  • Abuse potential assessment of novel central nervous system active and psychedelic substances for controlled substances act scheduling recommendations (2025)
    Journal of Psychopharmacology 5 citations DOI OpenAlex
  • Effects of psychostimulants on locomotor activity in the BTBR T+ Itpr3tf/J mouse: implications for comorbid autism spectrum disorder and attention deficit hyperactivity disorder (2025)
    Psychopharmacology DOI OpenAlex
  • In vitro and in vivo pharmacological characterization of fentanyl analogs (2025)
    Neuropharmacology 7 citations DOI OpenAlex
  • Effects of orally self-administered furanyl fentanyl and acryl fentanyl in mice: antinociception, dependence and withdrawal, and defense of consumption (2025)
    Neuropharmacology 4 citations DOI OpenAlex
  • Synthetic cannabinoid receptor agonists exacerbate fentanyl-elicited respiratory depression and confer resistance to naloxone rescue in mice (2025)
    Drug and Alcohol Dependence 5 citations DOI OpenAlex
  • NAPQI is absent in the mouse brain after sub-hepatotoxic and hepatotoxic doses of acetaminophen (2025)
    Toxicological Sciences 5 citations DOI OpenAlex
  • DRUG-DRUG INTERACTIONS RELEVANT TO SUBSTANCE ABUSE AND TOXICITY (2025)
    Drug and Alcohol Dependence DOI OpenAlex
  • A “Furious” Effort to Develop Novel 3,4-Methylenedioxymethamphetamine-Like Therapeutics (2024)
    Journal of Pharmacology and Experimental Therapeutics 1 citation DOI OpenAlex
  • Respiratory Depressant Effects of Fentanyl in Combination With Synthetic Cannabinoid Receptor Agonists: A Potential Mechanism for “Narcan-Resistant” Overdose (2024)
    Drug and Alcohol Dependence DOI OpenAlex
  • Erratum to “Effects of ambient temperature on locomotor activity and place conditioning elicited by abused psychostimulants in mice: Role of 3,4-methylenedioxy moiety” [Drug Alcohol Depend. 250 (2023) 110917] (2024)
    Drug and Alcohol Dependence DOI OpenAlex
  • Phencyclidine-Like Abuse Liability and Psychosis-Like Neurocognitive Effects of Novel Arylcyclohexylamine Drugs of Abuse in Rodents (2024)
    Journal of Pharmacology and Experimental Therapeutics 5 citations DOI OpenAlex

View all publications on OpenAlex →

Federal Grants 2 $864,148 total

NIH Contact PI Jul 2026 - Apr 2031

Abuse-related and neurocognitive consequences of halogenated arylcyclohexylamines.

National Institute on Drug Abuse $686,648 R01
NIH Contact PI Jul 2023 - Jun 2028

Training in Systems Pharmacology and Toxicology (T-SPaT)

National Institute of General Medical Sciences $177,500 T32

Grants & Funding

As listed on this researcher's institutional profile. Federal awards with verified records are shown above.

  • Translational Training in Addiction NIH/Nat. Inst. on Drug Abuse Principal Investigator
  • Effects of self-administered MDMA on brain and behavior in rhesus monkeys NIH Principal Investigator
  • In vivo pharmacological studies for abuse liability testing - Continuation U.S. Food and Drug Administration Principal Investigator
  • Translational training in addiction NIH/NIDA Other Key Personnel
  • INTRAVENOUS SELF ADMINISTRATION OF MDMA NIH Principal Investigator
  • Synthetic Cannabinoid Toxicity: Role of Biotransformation NIH Co-Investigator
  • Evaluation of Hallucinogenic Substances using the Drug Discrimination Assay US Department of Justice Principal Investigator
  • Evaluation of enantiomer combinations of MDXX drugs in mouse models of autism PharmAla Biotech Principal Investigator

Collaboration Network

85 Collaborators 33 Institutions 4 Countries

Top Collaborators

View profile →
View profile →
View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics